Scrip
Clinica
Scrip Regulatory Affairs
Scrip Clinical Research
AnimalPharm
Email ID
Password
Forgotten your password?
Sign me in automatically next time
Advanced Search
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Cancer
|
Cardiovascular
|
Infection
|
Metabolic
|
Musculoskeletal
|
CNS
|
Respiratory
|
Gastrointestinal
|
Other
|
Therapy Sector Stage - Cancer
About Us
Getting Started
Subscribe
Free Trial
Advertise
Awards
White Papers
Executive Briefing
Classifieds
Recruitment
JOB OF THE WEEK
Promote your vacancy here
SCRIP's ONLINE DIRECTORY
Classified ads
LATEST NEWS
Novartis' Votubia (everolimus) approved in Europe
08 September 2011
2011 US submission for Genentech/Curis' vismodegib in basal ...
NICE to review Fabre's Javlor again as comparison with unlic...
PHARMAC widens access to two cancer drugs
28 July 2011
EMA recommends 4SC's resminostat for orphan designation
28 July 2011
BioSante to begin Phase I trial of melanoma vaccine at Johns Hopkins
22 July 2011
Nordic to market Taiho anticancer in Europe
22 July 2011
>> More News...
LATEST ANALYSIS
Challenges and opportunities in the Philippine pharma market
08 January 2010
Risk sharing: Pharma's failure to prove its value
18 December 2009
2010 Scrip 100 - Little change in win, place or show
09 December 2009
>> More Analysis...
LATEST FEATURES
Archimedes – a fast mover in a niche sector
19 June 2009
Face-to-face: The FDA, Amgen, and its blockbuster biologic, denosumab
15 June 2009
Antibodies emerge as key focus for Kyowa Kirin
05 June 2009
>> More Features...
LATEST COMMENT
Dapagliflozin: 'No' from FDA advisers could spell trouble for new diabetes class
21 July 2011
Latvia makes healthcare budget cuts as economic crisis bites
16 June 2009
Cancer drugs: getting more for your money – by Karol Sikora
11 May 2009
>> More Comment...
REFINE BY
COMPANY/ORGANISATION
NOVARTIS
GLAXOSMITHKLINE
PFIZER
ASTRAZENECA
CONDITION
CANCER
BREAST CANCER
LUNG CANCER
PROSTATE CANCER
GEOGRAPHY
JAPAN
GERMANY
CANADA
CHINA
DRUG
BEVACIZUMAB
PACLITAXEL
TRASTUZUMAB
DOCETAXEL